FDA Approves Kebilidi for Aromatic L-Amino Acid Decarboxylase Deficiency

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 27, 2024.

By Lori Solomon HealthDay Reporter

TUESDAY, Nov. 26, 2024 -- The U.S. Food and Drug Administration has approved Kebilidi (eladocagene exuparvovec-tneq) for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency.

The adeno-associated virus vector-based gene therapy is the first FDA-approved gene therapy for treatment of AADC deficiency, a rare genetic disorder affecting the production of some neurotransmitters. Kebilidi needs to be administered in a medical center that specializes in pediatric stereotactic neurosurgery. In one surgical session, four infusions are delivered to the brain region involved in motor control.

The accelerated approval was based on an open-label, single-arm clinical study that included 13 pediatric patients with a confirmed diagnosis of AADC deficiency. At baseline, all patients had no gross motor function (the most severe presentation of AADC deficiency) and decreased AADC activity in the plasma. Compared with untreated patients (natural history), eight of 12 patients treated with Kebilidi exhibited improvement in gross motor function at week 48.

"Clinical advancements in the field of gene therapy continue to lead to the discovery and availability of innovative treatment options for rare diseases that are otherwise difficult to manage," Peter Marks, M.D., Ph.D., from the FDA Center for Biologics Evaluation and Research, said in a statement.

Approval of Kebilidi was granted to PTC Therapeutics.

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords